Literature DB >> 21253742

[Biologics. Magic bullets - magic effects - magic costs? New therapeutics and their effects].

O Frey1, T Kamradt.   

Abstract

Biologics and especially therapeutic monoclonal antibodies have an ever increasing impact in the therapy of inflammatory and malignant diseases. They allow a selective blockade of cytokines, receptors and other molecules. This review summarizes the immunological background, the current state and future trends in the development of these therapeutic agents.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21253742     DOI： 10.1007/s00347-010-2255-z

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  13 in total

Review 1.  The changing face of rheumatoid arthritis: sustained remission for all?

Authors:  John D Isaacs
Journal:  Nat Rev Immunol       Date:  2010-08       Impact factor: 53.106

Review 2.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

3.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

Review 4.  Monoclonal antibodies as innovative therapeutics.

Authors:  Janice M Reichert
Journal:  Curr Pharm Biotechnol       Date:  2008-12       Impact factor: 2.837

5.  Clinical comparability and European biosimilar regulations.

Authors:  Huub Schellekens; Ellen Moors
Journal:  Nat Biotechnol       Date:  2010-01       Impact factor: 54.908

Review 6.  [Monoclonal antibodies. Principles, generation, application, and side effects].

Authors:  U Sack; F Emmrich
Journal:  Internist (Berl)       Date:  2008-08       Impact factor: 0.743

7.  Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis.

Authors:  Stephan Blüml; Nikolaus B Binder; Birgit Niederreiter; Karin Polzer; Silvia Hayer; Stefanie Tauber; Georg Schett; Clemens Scheinecker; George Kollias; Edgar Selzer; Martin Bilban; Josef S Smolen; Giulio Superti-Furga; Kurt Redlich
Journal:  Arthritis Rheum       Date:  2010-06

8.  Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model.

Authors:  Cheryll Williams-Skipp; Thiagarajan Raman; Robert J Valuck; Herschel Watkins; Brent E Palmer; Robert I Scheinman
Journal:  Arthritis Rheum       Date:  2009-02

9.  Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.

Authors:  A Strangfeld; F Hierse; J Kekow; U von Hinueber; H-P Tony; R Dockhorn; J Listing; A Zink
Journal:  Ann Rheum Dis       Date:  2009-01-06       Impact factor: 19.103

Review 10.  Bispecific T-cell engaging antibodies for cancer therapy.

Authors:  Patrick A Baeuerle; Carsten Reinhardt
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.